Rakovina Therapeutics Inc. is a Canadian biopharmaceutical research company specializing in the development of innovative cancer therapies. The company focuses on exploiting novel small-molecule inhibitors targeting DNA-damage response (DDR) pathways, a key mechanism involved in cancer cell survival. Leveraging proprietary artificial intelligence technologies, including their Deep-Docking™ platform, Rakovina accelerates drug discovery and optimization to develop therapies aimed at treating various cancers, including those resistant to existing treatments. Among its preclinical pipeline are compounds such as the brain-penetrant PARP inhibitor kt-2000AI and next-generation drug candidates targeting PARP-resistant cancers and DNA repair mechanisms. With a strong scientific advisory board and collaborations in AI-driven drug development, Rakovina Therapeutics plays a significant role in advancing precision oncology through innovative DDR inhibitors. The company is headquartered in Vancouver, Canada, and is a subsidiary of NewGen Therapeutics, Inc.